PUBLISHER: Grand View Research | PRODUCT CODE: 2067525
PUBLISHER: Grand View Research | PRODUCT CODE: 2067525
The global drug discovery platforms market size was estimated at USD 3.4 billion in 2025 and is projected to reach USD 10.5 billion by 2033, growing at a CAGR of 15.1% from 2026 to 2033. The market growth is driven by several factors, including the increasing adoption of artificial intelligence (AI) and machine learning in drug discovery, rising pharmaceutical and biotechnology R&D investments, growing demand for precision medicine and targeted therapies, and advances in computational drug discovery.
The increasing adoption of AI and Machine Learning (ML) in drug discovery workflows is significantly driving the growth of the market. AI and ML-based platforms enable pharmaceutical and biotechnology companies to analyze large biological datasets, identify potential drug targets, and optimize lead compounds with greater speed and accuracy compared to conventional methods. These technologies support virtual screening, predictive toxicology, molecular modeling, and generative drug design, thereby reducing R&D costs and the time to molecule discovery.
In addition, AI-driven automation reduces clinical trial failure risks and improves decision-making efficiency. The growing demand for faster development of novel therapeutics, such as oncology and rare diseases, is further encouraging the adoption of AI-powered drug discovery platforms across the pharmaceutical industry. For instance, in January 2026, Pierre Fabre Laboratories and Iktos announced a collaboration for AI-driven drug discovery, aimed at developing novel small-molecule oncology therapies by combining computational design, biology, medicinal chemistry, medical science, and preclinical development capabilities.
This collaboration with Iktos marks an important milestone in our journey to build an AI-powered R&D engine at Pierre Fabre Laboratories. By integrating Iktos' generative AI and automated chemistry technologies into our research platforms, we are taking a step toward realizing our data and AI strategy. This cooperation exemplifies our ambition to leverage cutting-edge innovation to improve the quality and probability of success in drug discovery, while accelerating the delivery of meaningful advances for patients in oncology.
Audrey Kauffmann, Head of Data Science and Biometry at Pierre Fabre Medical Care R&D
Moreover, the rising demand for precision medicine and targeted therapies supports the growth of the drug discovery platforms market. Precision medicine develops treatments tailored to individual genetic profiles, biomarkers, and disease characteristics. This increases the adoption of AI-enabled drug discovery, genomics, bioinformatics, and multiomics technologies.
Drug discovery platforms support biomarker identification, molecular profiling, and patient stratification. This enables the development of highly targeted and effective therapies for diseases such as cancer, rare disorders, and neurological conditions. Consequently, pharmaceutical and biotechnology companies are increasingly investing in and collaborating on precision medicine-based drug development, supporting market growth. For instance, in March 2025, BostonGene Corporation announced a collaboration with Johnson & Johnson to evaluate biomarkers for colorectal cancer and multiple myeloma using AI-driven molecular profiling in clinical trials.
Similarly, in August 2024, BostonGene Corporation partnered with Takeda Pharmaceutical to evaluate immunotherapies using AI-powered molecular and immune profiling technologies. The collaboration focuses on improving patient selection, identifying predictive biomarkers for treatment response and toxicity, and enhancing clinical trial design through advanced multiomics and bioinformatics analysis. These partnerships aim to enhance patient stratification, optimize treatment selection, and identify predictive biomarkers through advanced molecular analytics.
Global Drug Discovery Platforms Market Report Segmentation
This report forecasts revenue growth and provides at the global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global drug discovery platforms market report based on drug type, application, therapeutic area, end use, and region: